Plus Therapeutics secures UnitedHealthcare coverage for brain cancer test

Plus Therapeutics Inc. (NASDAQ: PSTV) announced that its subsidiary CNSide Diagnostics has secured a national coverage agreement with UnitedHealthcare Insurance Company (NYSE: UNH) for its CNSide cerebrospinal fluid assay. The agreement, effective September 15, covers over 51 million people throughout the United States.

The CNSide cerebrospinal fluid tumor cell enumeration laboratory developed test is designed to diagnose and monitor treatment for patients with leptomeningeal metastases, a condition where cancer spreads to the central nervous system. The test analyzes cerebrospinal fluid to identify and count tumor cells.

According to the company, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020. Plus Therapeutics reports the test demonstrates 92% sensitivity and 95% specificity, and influences treatment decisions in 90% of cases.

The test is available exclusively through CNSide Diagnostics as a testing service provided to healthcare professionals in the United States. The company states that the clinical utility of CNSide over standard care has been documented in nine peer-reviewed publications and validated through the FORESEE clinical trial.

CNSide Diagnostics operates as a wholly-owned subsidiary of Plus Therapeutics, which is headquartered in Houston, Texas. Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers, with programs focused on leptomeningeal metastases and recurrent glioblastoma.

The information is based on a company press release statement.

You May Also Be Interested In